PeptiDream, a Tokyo-based biopharmaceutical company and Kleo Pharmaceuticals, a New Haven-based company using its proprietary Antibody Recruiting Molecule (ARM) and Synthetic Antibody Mimic (SyAM) platform technologies to develop small molecule immunotherapies (Kleo), announced a collaboration agreement to co-develop proprietary immune-oncology products in multiple indications.
Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify macrocyclic/constrained peptides against multiple oncology targets of interest selected by Kleo, and to optimize hit peptides into optimized binders that will be engineered by Kleo into novel ARM and SyAM products. Kleo will receive an upfront payment and will have the right to develop and commercialize all compounds resulting from the collaboration. PeptiDream is eligible to receive a tiered share of proceeds from any products that arise from the collaboration based on degree to which PeptiDream funds development of the product. Specific financial terms were not disclosed.